Skip Navigation



Annals of Oncology Advance Access published online on January 12, 2009
Annals of Oncology, doi:10.1093/annonc/mdn657
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
20/3/508    most recent
mdn657v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Noy, A.
Right arrow Articles by Yeung, H. W. D.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Noy, A.
Right arrow Articles by Yeung, H. W. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL)

A. Noy1,*, H. Schöder2, M. Gönen3, M. Weissler4, K. Ertelt5, C. Cohler6, C. Portlock1, P. Hamlin1 and H. W. D. Yeung2

1 Department of Medicine, Lymphoma Service
2 Department of Radiology, Nuclear Medicine
3 Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York
4 Department of Medicine, New York-Presbyterian, Weill-Cornell Medical Center, New York
5 Humboldt University, Berlin, Germany
6 University of Pennsylvania, Philadelphia, USA

* Correspondence to: Dr A. Noy, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. Tel: +1-212-639-7423; Fax: +1-646-422-2284; E-mail: noya{at}mskcc.org

Background: We previously correlated non-Hodgkin's lymphoma (NHL) histology with 18fluoro-2-deoxyglucose–positron emission tomography (FDG–PET) intensity: a standardized uptake value (SUV) >10 predicted aggressive lymphoma with >80% certainty and an SUV >13, with >90% certainty.

Patients and methods: To evaluate SUV in transformed lymphoma, we identified all FDG–PET scans for NHL at Memorial Sloan-Kettering Cancer 1999–2007 with (i) biopsy-proven transformation, (ii) no therapy 60 days before PET scan and (iii) FDG–PET scans no more than 60 days before or 90 days after transformation.

Results: In 5 of 40 patients, the biopsy site was excised before PET; in two, only marrow was biopsied. In the remaining 33 patients, the SUV of the biopsy site ranged from 3 to 38, mean 14, median 12. Eighteen of 33 biopsies (55%) had an SUV >10 and 16 (48%) >13. The highest SUV in a transformed lymphoma PET scan (SUVstudy-max) ranged from 3.2 to 40, mean 15, median 12. Twenty-five of 40 patients (63%) presented with an SUVstudy-max >10 and 20 (50%) >13.

Conclusions: Like de novo aggressive lymphomas, the majority of transformations have a high SUVstudy-max for a given pretreatment staging study, although many do not have very high values. Transformation should be suspected in indolent lymphoma with high SUVs on FDG–PET. Biopsies should be directed to the site of greatest FDG avidity.

18fluoro-2-deoxyglucose (FDG), lymphoma, positron emission tomography (PET), standardized uptake value (SUV), transformation

Received for publication May 4, 2008. Revision received August 18, 2008. Accepted for publication September 3, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.